UBS initiated coverage on PerkinElmer with a new price target
$PKI
Biotechnology: Laboratory Analytical Instruments
Industrials
UBS initiated coverage of PerkinElmer with a rating of Buy and set a new price target of $160.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/19/2022 | $170.00 | Sector Weight → Overweight | KeyBanc Capital Markets |
| 12/12/2022 | $135.00 → $170.00 | Neutral → Buy | Citigroup |
| 12/6/2022 | $192.00 → $164.00 | Market Perform → Outperform | Cowen |
| 11/28/2022 | $130.00 → $145.00 | Underweight → Equal Weight | Barclays |
| 8/25/2022 | $175.00 | Neutral | Credit Suisse |
| 8/18/2022 | $190.00 → $170.00 | Buy → Hold | Stifel |
| 8/2/2022 | $178.00 | Buy → Neutral | BofA Securities |
| 7/20/2022 | $160.00 | Buy | UBS |
KeyBanc Capital Markets upgraded PerkinElmer from Sector Weight to Overweight and set a new price target of $170.00
Citigroup upgraded PerkinElmer from Neutral to Buy and set a new price target of $170.00 from $135.00 previously
Cowen upgraded PerkinElmer from Market Perform to Outperform and set a new price target of $164.00 from $192.00 previously
Revenue of $675 million; (30)% reported growth; (27)% organic growth; 6% non-COVID organic growth GAAP EPS of $4.50; Adjusted EPS from continuing operations of $1.01 Updates full year 2023 guidance Authorizes new $600 million share repurchase program To begin trading under new ticker "RVTY" on May 16th Revvity, Inc. (NYSE:PKI), today reported financial results for the first quarter ended April 2, 2023. The Company reported GAAP earnings per share of $4.50, as compared to $1.40 in the same period a year ago. GAAP revenue for the quarter was $675 million, as compared to $963 million in the same period a year ago. GAAP operating income for the quarter was $76 million, as comp
Transformation aimed at revolutionizing next generation scientific breakthroughs that solve the world's greatest health challenges Trusted partner to pharma, government and diagnostics customers with complete, end-to-end solutions To begin trading as RVTY under new name on May 16th (NYSE:PKI) Revvity, Inc. officially launches today as a science-based solutions company that leverages innovation across life sciences and diagnostics to help improve lives everywhere. Born from two words, "revolutionize" (rev) and "vita" (vit) meaning "life" in Latin, Revvity delivers end-to-end expertise and solutions from research discovery to development, and diagnosis to cure. The Company was prev
Approximately $2.1 Billion in New Commitments Closed in the First Quarter and Approximately $23.5 Billion closed in the Last Twelve Months Ended March 31, 2023 Ares Management Corporation announced today that funds managed by its Credit Group (collectively "Ares") closed approximately $2.1 billion in U.S. direct lending commitments across 35 transactions during the first quarter of 2023 and approximately $23.5 billion in U.S. direct lending commitments across 189 transactions in the last twelve-month period ended March 31, 2023. Below is a description of selected transactions that Ares closed during the first quarter. Banyan Software Ares served as the agent, lead arranger and bookrun
8-K - REVVITY, INC. (0000031791) (Filer)
8-K - REVVITY, INC. (0000031791) (Filer)
8-K - REVVITY, INC. (0000031791) (Filer)
4 - REVVITY, INC. (0000031791) (Issuer)
4 - REVVITY, INC. (0000031791) (Issuer)
4 - REVVITY, INC. (0000031791) (Issuer)